Nuvo Research Inc. is a publicly traded, Canadian pharmaceutical company headquartered in Mississauga, Ontario with manufacturing facilities located in Varennes, Quebec and Wanzleben, Germany, and a research and development facility in San Diego, California.

Nuvo is focused on developing targeted therapeutic products designed to produce minimal side effects. The Company develops drugs based on two technology platforms: transdermal drug delivery and immune system regulation.

Nuvo is traded on the Toronto Stock Exchange under the symbol NRI.

Please follow the links in this section to obtain stock quotes, news releases, financial reports and other investor information.

To receive an investor package click here.

To view Nuvo's Canadian Reglatory filings, visit The System for Electronic Document Analysis and Retrieval (SEDAR) website.

Latest News:
August 1, 2008	Nuvo Announces Proposed Amendments to Outstanding Convertible Debentures
July 31, 2008	Nuvo Announces Second Quarter 2008 Financial Results
July 8, 2008	Nuvo Research and Paladin announce amendments to Pennsaid and Pennsaid Plus agreements

To see a complete listing of news releases click here.